SCHEMBL18632536

SCHEMBL18632536

COc1ccc(-c2ccc3n[nH]c(=O)n3c2)c(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 1/20 0.51
CHEK1 O14757 1/20 0.41
CDK4 P11802 1/20 0.40
CCND1 P24385 1/20 0.40
PRKAB2 O43741 1/20 0.39
PRKAG1 P54619 1/20 0.39
PRKAA2 P54646 1/20 0.39
PRKAA1 Q13131 1/20 0.39
PRKAG3 Q9UGI9 1/20 0.39
PRKAG2 Q9UGJ0 1/20 0.39
PRKAB1 Q9Y478 1/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
NOTUM Q6P988 1/20 0.38
FASN P49327 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2B Q13224 1/20 0.38
CRHR1 P34998 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18632513 0.78 SCN5A (0.49) SCN5ACHEK1NPC1RAB9ANOTUM
SCHEMBL30924244 0.73 SCN5A (0.47) SCN5ACHEK1NOTUMMAPTGSK3A
SCHEMBL18632542 0.71 SCN5A (0.61) SCN5ANPC1RAB9ANOTUM
SCHEMBL18632544 0.70 SCN5A (0.47) SCN5ACHEK1NOTUMGSK3A
SCHEMBL18632511 0.69 LTK (0.55) SCN5ACHEK1NOTUMTGFBR1
SCHEMBL18632525 0.69 SCN5A (0.51) SCN5ANOTUMGSK3B
SCHEMBL25835485 0.68 CYP1A2 (0.48) SCN5ACHEK1NOTUMCYP1A2MAPT
SCHEMBL10203097 0.68 SCN5A (0.61) SCN5ACHEK1MEN1KMT2ANPC1
SCHEMBL248547 0.68 SCN5A (1.00) SCN5ANOTUM
SCHEMBL253820 0.68 SCN5A (0.67) SCN5ACHEK1NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-03-23 US disclosed
WO-2017046318-A1 TRIAZOLONES DERIVATIVES FOR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2017-03-23 WO disclosed
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-03-23 US disclosed
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease OAT, XDH, MAPT SCN5A 1311/4885CHEK1 1722/4885CDK4 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.